Greenwich LifeSciences, Inc.
NASDAQ:GLSIBiotechnology
Healthcare
$19.79 -3.08%
-$0.74 today
- Market cap
- $290.48M
- Beta
- 1.38
- P/E (TTM)
- -15.6
- EPS (TTM)
- -$1.49
52W Low $7.78High $34.10
Volume 0.23M
Average 0.14M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$9.91M
FY 2025 · Annual
Investing Cash Flow
$0.00
FY 2025 · Annual
Financing Cash Flow
$12.00M
FY 2025 · Annual
+174.6% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (4.57M) | (7.83M) | (8.89M) | (15.79M) | (19.36M) |
| Depreciation & Amortization | 3.61K | 3.61K | 3.61K | 3.61K | 1.78K |
| Deferred Income Tax | (1.19M) | (1.75M) | 0 | 0 | 0 |
| Stock-Based Compensation | 660.58K | 1.74M | 2.38M | 7.25M | 6.8M |
| Change in Working Capital | (385.17K) | (122.27K) | 31.5K | 1.27M | 2.64M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (526.73K) | 0 | 35.47K | 921.22K | 2.07M |
| Other Working Capital | 141.57K | (122.27K) | (3.97K) | 344.11K | 568.12K |
| Other Non-Cash Items | 1.19M | 1.75M | 0 | 0 | 0 |
| Operating Cash Flow | (4.29M) | (6.2M) | (6.48M) | (7.27M) | (9.91M) |
| Capital Expenditures | 0 | (3) | 0 | 3 | 3 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 0 |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 3.11M | 0 | 0 | 4.37M | 12M |
| Common Stock Repurchased | 0 | (7.54M) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (275.15K) | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 2.84M | (7.54M) | 0 | 4.37M | 12M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (1.46M) | (13.74M) | (6.48M) | (2.9M) | 2.09M |
| Free Cash Flow | (4.29M) | (6.2M) | (6.48M) | (7.27M) | (9.91M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$19.4M
+ D&A$1.8K
+ Stock-Based Comp$6.8M
+ Deferred Tax$0
+ Working Capital$2.6M
+ Other Non-Cash$0
= Operating Cash Flow-$9.9M
- Capex$3
= Free Cash Flow-$9.9M
Analysis
FY2025 free cash flow is -$9.9M. FCF conversion is 51.2% of net income. Operating cash flow was -$9.9M, with capex of $3. The largest bridge item is Stock-Based Comp at $6.8M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| DEFA14A | DEFA14A filing | Oct 26, 2026 | |
| DEF 14A | DEF 14A filing | Oct 26, 2026 | |
| ARS | ARS filing | Oct 26, 2026 | |
| 10-Q | Quarterly report | Aug 11, 2026 | |
| 4 | Statement of changes in beneficial ownership | Jul 30, 2026 |
Does GLSI generate free cash flow?
Greenwich LifeSciences, Inc. (GLSI) generated -$9.91M of free cash flow in fiscal 2025.
How much operating cash flow does GLSI produce?
Operating cash flow was -$9.91M, before capital expenditures of $3.00.
Continue the stock analysis
Jump to another research area for this company.